Genetically predicted 17beta-estradiol and cardiovascular risk factors in women: A Mendelian randomization analysis using young women in Hong Kong and older women in the Guangzhou Biobank Cohort Study

Annals of Epidemiology

Volumn 26, Issue 3, 2016, Pages 171-175

  Au Yeung, Shiu Lun ^a   Cheng, Kar Keung ^b   Zhao, Jie ^a   Zhang, Weisen ^c   Jiang, Chaoqiang ^c   Lam, Tai Hing ^a   Leung, Gabriel Matthew ^a   Schooling, C Mary ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Guangzhou Number 12 Hospital   (China)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cardiovascular risk factors; Chinese; Estrogen; Mendelian randomization analysis; Women

Indexed keywords

ESTRADIOL; GENETIC MARKER;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; ESTRADIOL BLOOD LEVEL; FEMALE; FRAMINGHAM RISK SCORE; GENETIC RISK; GLUCOSE BLOOD LEVEL; HONG KONG; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; WAIST CIRCUMFERENCE; WAIST HIP RATIO; CARDIOVASCULAR DISEASES; CHINA; COHORT ANALYSIS; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHINA; COHORT STUDIES; ESTRADIOL; FEMALE; GENETIC MARKERS; HONG KONG; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 84960439148     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2016.01.005     Document Type: Article

References (36)

1. Casanova G., Bossardi Ramos R., Ziegelmann P., Spritzer P.M. Effects of low-dose versus placebo or conventional-dose postmenopausal hormone therapy on variables related to cardiovascular risk: a systematic review and meta-analyses of randomized clinical trials. J Clin Endocrinol Metab 2015, 100(3):1028-1037.
2. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013, 310(13):1353-1368.
3. Prentice R.L., Langer R., Stefanick M.L., Howard B.V., Pettinger M., Anderson G., et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005, 162(5):404-414.
4. Hodis H.N., Mack W.J., Shoupe D., Azen S.P., Stanczyk F.Z., Hwang-Levine J., et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause (New York, NY) 2015, 22(4):391-401.
5. Manson J.E., Bassuk S.S. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?. Am J Epidemiol 2007, 166(5):511-517.
6. Michels K.B. Hormone replacement therapy in epidemiologic studies and randomized clinical trials - are we checkmate?. Epidemiology 2003, 14(1):3-5.
7. Schooling C.M., Freeman G., Cowling B.J. Mendelian randomization and estimation of treatment efficacy for chronic diseases. Am J Epidemiol 2013, 177(10):1128-1133.
8. Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N., Davey-Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008, 27(8):1133-1163.
9. Wensley F., Gao P., Burgess S., Kaptoge S., Di Angelantonio E., Shah T., et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011, 342:d548.
10. Schooling C.M., Au Yeung S.L., Freeman G. Mendelian Randomization Estimates May Be Inflated. J Am Coll Cardiol 2013, 61(18):1931.
11. Pierce B.L., Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013, 178(7):1177-1184.
12. Zhao J., Jiang C., Lam T.H., Liu B., Cheng K.K., Xu L., et al. Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol 2014, 43(1):140-148.
13. Zhao J., Jiang C.Q., Lam T.H., Liu B., Cheng K.K., Kavikondala S., et al. Genetically predicted 17beta-estradiol and systemic inflammation in women: a separate-sample Mendelian randomisation analysis in the Guangzhou Biobank Cohort Study. J Epidemiol Community Health 2014, 68(8):780-785.
14. Zhao J., Jiang C., Lam T.H., Liu B., Cheng K.K., Xu L., et al. Genetically predicted testosterone and systemic inflammation in men: a separate-sample Mendelian randomization analysis in older Chinese men. PLoS One 2015, 10(5):e0126442.
15. Tsang S.Y.-S. A modern history of Hong Kong 2004, I.B. Tauris, London; New York, xi, 340.
16. Jiang C., Thomas G.N., Lam T.H., Schooling C.M., Zhang W., Lao X., et al. Cohort profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration. Int J Epidemiol 2006, 35(4):844-852.
17. Au Yeung S.L., Jiang C.Q., Cheng K.K., Liu B., Zhang W.S., Lam T.H., et al. Evaluation of moderate alcohol use and cognitive function among men using a Mendelian randomization design in the Guangzhou Biobank Cohort Study. Am J Epidemiol 2012, 175(10):1021-1028.
18. Breast, Prostate Cancer Cohort Consortium, Cox D.G., Bretsky P., Kraft P., Pharoah P., et al. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer 2008, 122(2):387-392.
19. Lundin E., Wirgin I., Lukanova A., Afanasyeva Y., Krogh V., Axelsson T., et al. Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer. Cancer Epidemiol 2012, 36(5):445-452.
20. Udler M.S., Azzato E.M., Healey C.S., Ahmed S., Pooley K.A., Greenberg D., et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 2009, 125(11):2687-2696.
21. Talbott K.E., Gammon M.D., Kibriya M.G., Chen Y., Teitelbaum S.L., Long C.M., et al. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat 2008, 111(3):481-487.
22. National Centre for Biotechnology Information Database of single nucleotide polymorphisms (SNPs). Available from: . http://www.ncbi.nlm.nih.gov/snp.
23. Liu J., Hong Y., D'Agostino R.B., Wu Z., Wang W., Sun J., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004, 291(21):2591-2599.
24. Wooldridge J.M. Introductory econometrics: a modern approach 2009, Cengage Learning, Mason, OH: South Western, xx, 865. 4th ed.
25. Marijon E., Mirabel M., Celermajer D.S., Jouven X. Rheumatic heart disease. Lancet 2012, 379(9819):953-964.
26. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006, 8(5):538-554.
27. Bonds D.E., Lasser N., Qi L., Brzyski R., Caan B., Heiss G., et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 2006, 49(3):459-468.
28. Prentice R.L., Langer R.D., Stefanick M.L., Howard B.V., Pettinger M., Anderson G.L., et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006, 163(7):589-599.
29. Zimmerman Y., Eijkemans M.J., Coelingh Bennink H.J., Blankenstein M.A., Fauser B.C. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014, 20(1):76-105.
30. Curb J.D., Prentice R.L., Bray P.F., Langer R.D., Van Horn L., Barnabei V.M., et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006, 166(7):772-780.
31. Freeman G., Cowling B.J., Schooling C.M. Power and sample size calculations for Mendelian randomization studies using one genetic instrument. Int J Epidemiol 2013, 42(4):1157-1163.
32. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998, 351(9113):1425-1427.
33. Petitti D. Commentary: hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol 2004, 33(3):461-463.
34. Lawlor D.A., Davey-Smith G., Ebrahim S. Socioeconomic position and hormone replacement therapy use: Explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health 2004, 94(12):2149-2154.
35. Petitti D.B., Freedman D.A. Invited commentary: how far can epidemiologists get with statistical adjustment?. Am J Epidemiol 2005, 162(5):415-418. discussion 9-20.
36. Shufelt C.L., Bairey Merz C.N. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009, 53(3):221-231.